$194 Million is the total value of Tamarack Advisers, LP's 36 reported holdings in Q4 2022. The portfolio turnover from Q3 2022 to Q4 2022 was 52.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | QQQ Jan3 270.0 Pput | $39,942,000 | – | 150,000 | +100.0% | 20.57% | – | |
| MDRX | Buy | VERADIGM ORDequity | $12,612,600 | +20.9% | 715,000 | +4.4% | 6.50% | +6.0% |
| VTRS | Buy | VIATRIS ORDequity | $10,851,750 | +96.0% | 975,000 | +50.0% | 5.59% | +71.8% |
| Buy | SPY Jan3 380.0 Pput | $9,560,750 | +7548.6% | 25,000 | +900.0% | 4.92% | +6643.8% | |
| PHR | Buy | PHREESIA ORDequity | $9,222,600 | +39.2% | 285,000 | +9.6% | 4.75% | +22.1% |
| CERS | Buy | CERUS ORDequity | $9,125,000 | +4.5% | 2,500,000 | +3.1% | 4.70% | -8.3% |
| COLL | Buy | COLLEGIUM PHARMACEUTICAL ORDequity | $8,978,400 | +86.8% | 387,000 | +29.0% | 4.62% | +63.8% |
| STRM | STREAMLINE HEALTH SOLUTIONS ORDequity | $7,790,794 | +32.8% | 4,930,882 | 0.0% | 4.01% | +16.5% | |
| ALKS | Buy | ALKERMES ORDequity | $7,185,750 | +60.9% | 275,000 | +37.5% | 3.70% | +41.1% |
| ANGO | Buy | ANGIODYNAMICS ORDequity | $6,747,300 | +1.5% | 490,000 | +50.8% | 3.48% | -11.0% |
| Buy | BDX Jan3 260.0 Pput | $6,357,500 | +834.9% | 25,000 | +12400.0% | 3.27% | +720.6% | |
| BIIB | New | BIOGEN ORDequity | $5,538,400 | – | 20,000 | +100.0% | 2.85% | – |
| ASND | Buy | ASCENDIS PHARMA ADR REP ORDequity | $5,495,850 | +254.8% | 45,000 | +200.0% | 2.83% | +211.3% |
| LNTH | Sell | LANTHEUS HOLDINGS ORDequity | $5,350,800 | -63.4% | 105,000 | -49.5% | 2.76% | -67.9% |
| THC | Sell | TENET HEALTHCARE ORDequity | $4,635,050 | -48.7% | 95,000 | -45.7% | 2.39% | -55.0% |
| SIBN | Sell | SI BONE ORDequity | $4,488,000 | -44.1% | 330,000 | -28.3% | 2.31% | -51.0% |
| PCRX | Sell | PACIRA BIOSCIENCES ORDequity | $3,861,000 | -62.8% | 100,000 | -48.7% | 1.99% | -67.4% |
| NEOG | New | NEOGEN ORDequity | $3,807,500 | – | 250,000 | +100.0% | 1.96% | – |
| RIGL | Buy | RIGEL PHARMACEUTICALS ORDequity | $3,450,000 | +46.2% | 2,300,000 | +15.0% | 1.78% | +28.2% |
| INMD | New | INMODE ORDequity | $3,213,000 | – | 90,000 | +100.0% | 1.66% | – |
| TCMD | Buy | TACTILE SYSTEMS TECHNOLOGY ORDequity | $2,927,400 | +67.0% | 255,000 | +13.3% | 1.51% | +46.5% |
| MRK | MERCK & CO ORDequity | $2,773,750 | +28.8% | 25,000 | 0.0% | 1.43% | +13.0% | |
| TPB | Sell | TURNING POINT BRANDS ORDequity | $2,703,750 | -22.8% | 125,000 | -24.2% | 1.39% | -32.3% |
| DOCGO ORDequity | $2,651,250 | -28.7% | 375,000 | 0.0% | 1.36% | -37.5% | ||
| SNY | Sell | SANOFI ADR REP 1 1/2 ORDequity | $2,421,500 | -58.9% | 50,000 | -67.7% | 1.25% | -64.0% |
| ATRC | Sell | ATRICURE ORDequity | $2,219,000 | -15.9% | 50,000 | -25.9% | 1.14% | -26.2% |
| IRWD | New | IRONWOOD PHARMA CL A ORDequity | $2,168,250 | – | 175,000 | +100.0% | 1.12% | – |
| FENC | Buy | FENNEC PHARMACEUTICALS ORDequity | $2,044,800 | +44.2% | 213,000 | +21.7% | 1.05% | +26.4% |
| RDNT | Buy | RADNET ORDequity | $1,883,000 | +54.2% | 100,000 | +66.7% | 0.97% | +35.3% |
| PLXS | Sell | PLEXUS ORDequity | $1,595,415 | -8.9% | 15,500 | -22.5% | 0.82% | -20.0% |
| ICUI | Sell | ICU MEDICAL ORDequity | $787,400 | -65.1% | 5,000 | -66.7% | 0.40% | -69.5% |
| Sell | SOMALOGIC CL A ORDequity | $627,500 | -27.9% | 250,000 | -16.7% | 0.32% | -36.8% | |
| Buy | MAXCYTE ORDequity | $546,000 | +2.2% | 100,000 | +21.8% | 0.28% | -10.5% | |
| CDNA | Buy | CAREDX ORDequity | $342,300 | -19.6% | 30,000 | +20.0% | 0.18% | -29.6% |
| NSTG | New | NANOSTRING TECHNOLOGIES ORDequity | $239,100 | – | 30,000 | +100.0% | 0.12% | – |
| New | SOMALOGIC EQY WARRANTcall | $50,200 | – | 20,000 | +100.0% | 0.03% | – | |
| Exit | CM LIFE SCIENCES II -CW27warrant | $0 | – | -20,000 | -100.0% | -0.01% | – | |
| Exit | VTRS US 10/21/22 C12call | $0 | – | -4,000 | -100.0% | -0.02% | – | |
| Exit | TLT US 11/18/22 C125call | $0 | – | -4,000 | -100.0% | -0.04% | – | |
| Exit | TERRASCEND CORPequity | $0 | – | -75,000 | -100.0% | -0.06% | – | |
| VRAY | Exit | VIEWRAY INCequity | $0 | – | -100,000 | -100.0% | -0.21% | – |
| Exit | DERMTECH INCequity | $0 | – | -175,000 | -100.0% | -0.41% | – | |
| NVST | Exit | ENVISTA HOLDINGS CORPequity | $0 | – | -25,000 | -100.0% | -0.48% | – |
| BIO | Exit | BIO-RAD LABORATORIES-Aequity | $0 | – | -2,000 | -100.0% | -0.49% | – |
| ISEE | Exit | IVERIC BIO INCequity | $0 | – | -50,000 | -100.0% | -0.53% | – |
| IQV | Exit | IQVIA HOLDINGS INCequity | $0 | – | -10,000 | -100.0% | -1.06% | – |
| MOH | Exit | MOLINA HEALTHCARE INCequity | $0 | – | -6,000 | -100.0% | -1.16% | – |
| JAZZ | Exit | JAZZ PHARMACEUTICALS PLCequity | $0 | – | -30,000 | -100.0% | -2.35% | – |
| CVS | Exit | CVS HEALTH CORPequity | $0 | – | -50,000 | -100.0% | -2.80% | – |
| BVS | Exit | BIOVENTUS INC - Aequity | $0 | – | -750,001 | -100.0% | -3.08% | – |
| CI | Exit | CIGNA CORPequity | $0 | – | -20,000 | -100.0% | -3.26% | – |
| BMRN | Exit | BIOMARIN PHARMACEUTICAL INCequity | $0 | – | -71,000 | -100.0% | -3.53% | – |
| PRGO | Exit | PERRIGO CO PLCequity | $0 | – | -255,000 | -100.0% | -5.34% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-02-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| VERADIGM ORD | 32 | Q3 2023 | 13.9% |
| STREAMLINE HEALTH SOLUTIONS ORD | 30 | Q3 2023 | 4.0% |
| ATRICURE ORD | 29 | Q3 2023 | 7.6% |
| PACIRA PHARMACEUTICALS INC | 27 | Q1 2023 | 12.1% |
| LANTHEUS HOLDINGS ORD | 25 | Q4 2022 | 9.6% |
| MEDTRONIC PLC | 21 | Q1 2022 | 12.7% |
| RIGEL PHARMACEUTICALS ORD | 21 | Q2 2023 | 8.0% |
| BIO RAD LABORATORIES CL A ORD | 19 | Q2 2023 | 10.0% |
| HOLOGIC INC | 17 | Q1 2022 | 6.5% |
| SPY US 10/21/16 P210 | 17 | Q3 2023 | 41.5% |
View Tamarack Advisers, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| STREAMLINE HEALTH SOLUTIONS INC. | June 22, 2023 | 5,514,515 | 9.4% |
| IVERIC bio, Inc. | February 16, 2021 | 850,000 | 0.1% |
| Correvio Pharma Corp. | February 14, 2020 | 2,500,000 | 4.9% |
| OBALON THERAPEUTICS INC | February 14, 2020 | ? | ? |
| Correvio Pharma Corp. | February 15, 2019 | ? | ? |
| Corium International, Inc. | February 15, 2017 | 737,242 | 3.3% |
| ENDOLOGIX INC /DE/Sold out | February 15, 2017 | 0 | 0.0% |
| Imprivata IncSold out | February 15, 2017 | 0 | 0.0% |
View Tamarack Advisers, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-09 |
| 13F-HR | 2023-11-16 |
| 13F-HR | 2023-08-10 |
| SC 13D/A | 2023-06-22 |
| 13F-HR | 2023-05-11 |
| 13F-HR | 2023-02-13 |
| SC 13D/A | 2022-12-01 |
| 13F-HR | 2022-11-15 |
| 13F-HR | 2022-08-16 |
| 13F-HR | 2022-05-11 |
View Tamarack Advisers, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.